Bempedoic Acid for Primary Prevention of Cardiovascular Events in Statin-Intolerant Patients.

ABSTRACT:

Importance

The effects of bempedoic acid on cardiovascular outcomes in statin-intolerant patients without a prior cardiovascular event (primary prevention) have not been fully described.

Objective

To determine the effects of bempedoic acid on cardiovascular outcomes in primary prevention patients.

Design, setting, and participants

This masked, randomized clinical trial enrolled 13 970 statin-intolerant patients (enrollment December 2016 to August 2019 at 1250 centers in 32 countries), including 4206 primary prevention patients.

Interventions

Participants were randomized to oral bempedoic acid, 180 mg daily (n = 2100), or matching placebo (n = 2106).

Main outcome measures

The primary efficacy measure was the time from randomization to the first occurrence

SUBMITTER: Nissen SE 

PROVIDER: S-EPMC10336623 | biostudies-literature | 2023 Jul

REPOSITORIES: biostudies-literature